KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 60 filers reported holding KINNATE BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is 0.76 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $5,232,420 | +69.3% | 2,207,772 | 0.0% | 6.23% | +30.2% |
| Q3 2023 | $3,090,881 | -53.8% | 2,207,772 | 0.0% | 4.78% | -45.2% |
| Q2 2023 | $6,689,549 | -51.5% | 2,207,772 | 0.0% | 8.73% | -53.7% |
| Q1 2023 | $13,798,575 | +2.5% | 2,207,772 | 0.0% | 18.88% | +4.3% |
| Q4 2022 | $13,467,409 | -49.0% | 2,207,772 | 0.0% | 18.10% | -23.6% |
| Q3 2022 | $26,383,000 | -23.8% | 2,207,772 | -19.6% | 23.68% | -19.1% |
| Q2 2022 | $34,645,000 | +12.0% | 2,747,433 | 0.0% | 29.28% | +62.7% |
| Q1 2022 | $30,936,000 | -36.5% | 2,747,433 | 0.0% | 17.99% | -1.2% |
| Q4 2021 | $48,685,000 | -23.0% | 2,747,433 | 0.0% | 18.21% | +0.5% |
| Q3 2021 | $63,246,000 | -1.1% | 2,747,433 | 0.0% | 18.11% | +13.0% |
| Q2 2021 | $63,960,000 | -25.3% | 2,747,433 | 0.0% | 16.04% | -25.8% |
| Q1 2021 | $85,610,000 | -21.7% | 2,747,433 | +0.0% | 21.63% | -3.6% |
| Q4 2020 | $109,279,000 | – | 2,747,074 | – | 22.43% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $60,447,769 | 31.36% |
| Vida Ventures Advisors, LLC | 2,207,772 | $13,798,575 | 18.88% |
| Lynx1 Capital Management LP | 2,214,250 | $13,839,063 | 11.54% |
| Foresite Capital Management V, LLC | 1,975,001 | $12,343,756 | 9.12% |
| Nextech Invest Ltd. | 2,329,480 | $14,559,250 | 6.08% |
| Ally Bridge Group (NY) LLC | 109,393 | $683,706 | 0.90% |
| Orbimed Advisors | 5,143,629 | $32,147,681 | 0.63% |
| RA Capital Management | 4,264,144 | $26,650,900 | 0.60% |
| Novo Holdings A/S | 815,707 | $5,098,169 | 0.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $3,112,506 | 0.33% |